Requiring high quality clinical trials in China is essential to the safe and effective use of drugs, yet it must be remembered that China is still a developing country. This paper describes the mechanism and procedures for new drug approval, as well as the development of good clinical practice (GCP) in China. Descriptions of each of the 13 chapters of the Chinese GCP are included. The current status of and problems with GCP implementation in China are covered.
Facts and figures: Status of China's economic and social development in the world. Beijing Rev.1996; 39(10):22–23.
2.
Population pyramid in 1994 and Population Natural Change from 1984–1994. Beijing: China Population Information Center; 1995.
3.
LiLDZhangSW. The primary results of death causes from a randomized sample population in 26 provinces, autonomous regions and municipalities directly under the central government in China. Bull Chinese Can.1996;5(4):6–10.
4.
Scrip.1994;1891:23.
5.
GuoFW. A simple method to predict China's domestic drug marekt size. Chinese Pharma Inf.1996;2(1): 15–21.
6.
Provisions for New Drug Approval.The People's Republic of China: Ministry of Public Health; July 1, 1985.
7.
Regulations governing the registration, import, and clinical trials in China for foreign drugs.The People's Republic of China: Ministry of Public Health; February 2, 1988.
8.
KongYM. Current status and analysis of Chinese new drug (Western) development in the past ten years. Chinese Pharma Aff.1995;9(3): 142–147.
